Drug Trial Radar · NCT06653738
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 2, 2026
Primary completion
Sep 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- Insel Gruppe AG, University Hospital BernAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones. Study interventions: * Empagliflozin 10 mg once daily per os for 36 months * Personalized dietary counseling for 36 months. Control interventions: * Placebo once daily per os for 36 months * Generic dietary counseling for 36 months.
Conditions
- Kidney Stone
- Nephrolithiasis
- Dietary Exposure
Interventions
Empagliflozin 10 MGDrug
Once daily per os for 3 years
PlaceboDrug
Once daily per os for 3 years
Personalized dietary counselingBehavioral
Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
Generic dietary counselingBehavioral
Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with radiologic stone recurrenceTime frame: After 3 years
Locations
21 sites in 4 countries. Site status is shown where the registry gives one.
University Hospital Amiens-Picardie
Amiens, France · Not yet recruiting
Hôpital Tenon
Paris, France · Not yet recruiting
Hôpital Européen Georges Pompidou
Paris, France · Not yet recruiting
Charité University Medicine Berlin
Berlin, Germany · Not yet recruiting
Università della Campania "Luigi Vanvitelli"
Naples, Italy · Not yet recruiting
Verona University Hospital
Verona, Italy · Not yet recruiting
Kantonsspital Aarau
Aarau, Switzerland · Recruiting
Kantonsspital Baden
Baden, Switzerland · Recruiting
University Hospital Basel
Basel, Switzerland · Recruiting
Inselspital Bern
Bern, Switzerland · Recruiting
Kantonsspital Chur
Chur, Switzerland · Recruiting
Kantonsspital Fribourg
Fribourg, Switzerland · Not yet recruiting
University Hospital Geneva (HUG)
Geneva, Switzerland · Recruiting
Lausanne University Hospital (CHUV)
Lausanne, Switzerland · Recruiting
Kantonsspital Luzern
Lucerne, Switzerland · Not yet recruiting
Regionalspital Lugano
Lugano, Switzerland · Not yet recruiting
Kantonsspital Neuchâtel
Neuchâtel, Switzerland · Not yet recruiting
Kantonsspital Olten
Olten, Switzerland · Not yet recruiting
Kantonsspital St. Gallen
Sankt Gallen, Switzerland · Recruiting
Kantonsspital Sion
Sion, Switzerland · Not yet recruiting
Universitätsspital Zürich
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.